Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86VQ0
UPID:
LCA5_HUMAN
Alternative names:
Leber congenital amaurosis 5 protein
Alternative UPACC:
Q86VQ0; E1P542; Q9BWX7
Background:
Lebercilin, also known as Leber congenital amaurosis 5 protein, plays a crucial role in intraflagellar transport within photoreceptor cilia. This process is vital for the maintenance and function of cilia, which are essential for cellular signaling and movement.
Therapeutic significance:
Lebercilin's involvement in Leber congenital amaurosis 5, a severe dystrophy of the retina, highlights its potential as a target for therapeutic intervention. Understanding Lebercilin's function could lead to novel treatments for this debilitating condition.